Saturday 17 October 2026
Export SNDX’s income statement to Excel — free account
Syndax Pharmaceuticals, Inc.
SNDX Healthcare Biotechnology
Syndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024. In the quarter to June 2026, revenue grew 91.8%, EPS grew 33.7%, free cash flow grew 65.5% and total debt rose 71.0%, each against the same quarter a year earlier.
12.90
0.75
−5.49%
Follow SNDX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 50.91 | — | — | 0.00 | 0.00 |
Piotroski F-Score |
— | 3 | 2 | 2 | 3 | 7 | — | — | — | — |
Altman Z-Score |
(1.63) | (0.82) | (7.14) | (8.02) | 9.07 | 16.51 | — | — | (1.49) | (2.09) |
P/S ratio |
87.72 | 87.35 | 74.43 | 176.47 | 605.60 | 8.16 | — | — | 7.53 | 10.56 |
Altman Z″-Score (non-manufacturers) |
(2.37) | (2.78) | (16.08) | (25.93) | 3.82 | 13.07 | — | — | (3.43) | (7.54) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
P/Operating CF |
(10.27) | (14.47) | (7.51) | (21.03) | (58.77) | 11.32 | — | — | (19.72) | (26.19) |
Beneish M-Score |
— | 1.47 | (3.76) | (1.72) | (2.18) | 77.70 | — | — | — | 3.29 |
P/B ratio |
1.27 | 1.77 | 2.13 | 8.47 | 3.64 | 2.79 | — | — | 3.93 | 28.16 |
Price to Tangible BV |
1.27 | 1.77 | 2.13 | 8.47 | 3.64 | 2.79 | — | — | 3.93 | 28.16 |
EV/Sales |
12.63 | 32.23 | 30.17 | 137.66 | 425.60 | 5.10 | — | — | 5.94 | 10.29 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.50 | — | — | 0.00 | 0.00 |
EV/Operating CF |
(0.44) | (1.43) | (0.67) | (4.13) | (9.06) | 24.48 | — | — | (3.25) | (5.49) |
EV/FCF |
(0.43) | (1.43) | (0.67) | (4.11) | (9.04) | (7.31) | — | — | (2.03) | (5.49) |
Quick Ratio |
10.21 | 8.26 | 5.05 | 3.26 | 15.54 | 21.63 | 16.79 | 9.94 | 5.74 | 4.01 |
Current Ratio |
10.47 | 8.45 | 5.18 | 3.39 | 15.84 | 21.68 | 16.85 | 10.00 | 5.82 | 4.40 |
Net Debt/EBITDA |
2.41 | 2.11 | 1.06 | 1.01 | 3.82 | (15.87) | 3.12 | 2.36 | 0.68 | 0.25 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1.41% | 6.69% | 4.42% | 0.00% | 0.00% | 47.42% | 64.92% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.03 | 0.08 | 0.05 | 0.00 | 0.00 | 1.19 | 5.32 |
Asset Turnover |
0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.37 | 0.00 | 0.00 | 0.04 | 0.27 |
Operating CF/Net income |
0.75 | 0.78 | 0.93 | 0.90 | 0.92 | 1.17 | 0.90 | 0.77 | 0.86 | 1.13 |
Capex/Depreciation |
7.05 | (0.28) | 0.39 | 0.00 | 0.00 | (0.19) | (0.07) | 0.00 | 0.00 | 0.02 |
Interest Coverage |
(45.78) | (43.60) | (39.07) | (36.63) | (30.30) | 13.81 | (48.38) | (636.99) | (65.61) | (7.79) |
| 53.64% | (64.53%) | (94.00%) | (132.43%) | (54.31%) | 7.55% | (34.10%) | (40.98%) | (75.69%) | (161.82%) | |
| (47.33%) | (49.39%) | (66.90%) | (76.02%) | (42.33%) | 6.64% | (31.54%) | (37.72%) | (47.66%) | (45.50%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (434.21%) | 0.00% |
Return on Tangible Assets |
(47.83%) | (51.57%) | (109.39%) | (126.68%) | (27.50%) | 5.82% | (32.41%) | (40.05%) | (63.81%) | (69.93%) |
Average Days of Receivables |
91.55 | 65.28 | 60.87 | 27.91 | 42.11 | 1.12 | 0.00 | — | 173.21 | 144.31 |
Research and Development Expense of Revenue |
2,595.49% | 2,286.57% | 3,962.16% | 2,834.15% | 3,324.65% | 63.17% | 0.00% | 0.00% | 1,020.47% | 150.15% |
Selling, General and Administrative Expense of Revenue |
1,091.89% | 752.42% | 1,139.55% | 1,058.80% | 1,483.52% | 18.07% | 0.00% | 0.00% | 510.47% | 104.25% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
385.90% | 258.54% | 408.77% | 395.85% | 597.03% | 9.53% | 0.00% | 0.00% | 181.70% | 27.56% |
Graham Net Nets |
0.78 | 0.55 | 0.46 | 0.11 | 0.27 | 0.36 | — | — | 0.15 | 0.03 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.71 | — | — | 0.00 | 0.00 |
Earnings Yield |
(64.89%) | (32.95%) | (65.39%) | (21.07%) | (8.45%) | 1.96% | — | — | (28.21%) | (15.66%) |
Free Cash Flow Yield |
(33.10%) | (25.80%) | (60.86%) | (18.98%) | (7.78%) | (8.56%) | — | — | (38.82%) | (17.74%) |
Revenue per Share |
0.08 | 0.10 | 0.06 | 0.05 | 0.04 | 2.68 | 0.00 | 0.00 | 0.28 | 1.99 |
Operating CF per Share |
(2.40) | (2.26) | (2.70) | (1.66) | (1.73) | 0.56 | (2.20) | (2.28) | (3.21) | (3.73) |
Capex per Share |
(0.02) | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(2.42) | (2.26) | (2.71) | (1.66) | (1.73) | 0.56 | (2.20) | (2.28) | (3.21) | (3.73) |
Cash per Share |
7.21 | 6.20 | 3.19 | 1.96 | 7.10 | 8.58 | 7.97 | 8.21 | 6.81 | 4.78 |
Shareholders Equity per Share |
5.76 | 4.97 | 2.09 | 1.04 | 6.11 | 7.84 | 7.69 | 7.88 | 3.37 | 0.75 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.76 | 4.97 | 2.09 | 1.04 | 6.11 | 7.84 | 7.69 | 7.88 | 3.37 | 0.75 |
Free Cash Flow |
(35.42) | (47.45) | (68.72) | (50.61) | (71.26) | 29.00 | (133.45) | (160.60) | (274.90) | (323.17) |
Working Capital |
98.14 | 117.64 | 67.24 | 43.96 | 279.99 | 427.71 | 460.72 | 522.78 | 499.51 | 407.97 |
Capital Expenditures |
(0.26) | (0.08) | (0.19) | — | — | (0.13) | 0.23 | — | — | (0.19) |
Net Current Asset Value |
83.64 | 100.58 | 52.46 | 30.41 | 250.44 | 407.11 | 460.00 | 522.19 | 166.37 | 63.01 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.19 | — | — | 0.00 | 0.00 |
Capex to Sales |
0.21 | 0.04 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.47 | — | — | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(0.14) | 1.12 | (1.29) | (2.45) | (0.21) | 2.47 | (167.45) | (1,848.87) | 0.00 | (58.12) |
Cash ROIC |
(18.68%) | (20.25%) | (51.26%) | (54.85%) | (12.60%) | 3.31% | (14.02%) | (14.19%) | (22.63%) | (39.30%) |
Accounts Receivable Turnover |
3.57 | 6.17 | 4.82 | 8.22 | 10.43 | 462.61 | 0.00 | — | 3.22 | 4.34 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.09 | 0.00 | 0.08 | 0.49 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.42 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,537.69 | 3,497.25 | 0.00 | 5,137.40 | 868.25 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | 161.73 | 1,715.24 |
Average Receivables |
0.34 | 0.34 | 0.32 | 0.18 | 0.15 | 0.30 | 1.95 | — | 7.36 | 39.69 |
Average Payables |
1.91 | 2.30 | 1.84 | 3.81 | 4.84 | 4.59 | 5.01 | 7.16 | 10.79 | 14.10 |
Average Inventory |
— | — | — | — | — | — | — | — | — | 16.56 |
Average Assets |
99.46 | 123.10 | 110.56 | 73.73 | 182.07 | 375.14 | 473.45 | 555.06 | 668.85 | 627.26 |
Average Common Equity |
(87.75) | 94.23 | 78.68 | 42.32 | 141.89 | 330.28 | 437.91 | 510.82 | 421.16 | 176.38 |
Columns are period end dates